Published in Healthcare Mergers, Acquisitions and Ventures Week, May 19th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at OccuLogix.
Report 1: OccuLogix, Inc. (OCCX) has obtained Investigational Device Exemption clearance from the U.S. Food and Drug Administration (FDA) to commence its pivotal (phase III) study of the RHEOTM procedure to treat the dry form of age-related macular degeneration.
The new study, called RHEO-AMD, is a multi-center, prospective, randomized (2:1), double-masked, sham-controlled trial designed to evaluate the safety and efficacy of the RHEOTM procedure in patients with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.